Beijing InnoCare Pharma Raises $55 Million in Vivo-led Round

Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital and joined by CCB Capital. InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research. The company hopes its candidates, which target both China and global markets, will prove to be either first-in-class or best-in-class. InnoCare expects to release "landmark" clinical trial results this year. More details....

Share this with colleagues:

Original Article: Beijing InnoCare Pharma Raises $55 Million in Vivo-led Round

More From BioPortfolio on "Beijing InnoCare Pharma Raises $55 Million in Vivo-led Round"